B
Brett P. Monia
Researcher at Isis Pharmaceuticals
Publications - 302
Citations - 21990
Brett P. Monia is an academic researcher from Isis Pharmaceuticals. The author has contributed to research in topics: Oligonucleotide & Cancer. The author has an hindex of 70, co-authored 300 publications receiving 20496 citations. Previous affiliations of Brett P. Monia include University of Texas MD Anderson Cancer Center & Western General Hospital.
Papers
More filters
Journal ArticleDOI
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting.
Christine Esau,Scott Davis,Susan F. Murray,Xing Xian Yu,Sanjay K. Pandey,Michael Pear,Lynnetta Watts,Sheri L. Booten,Mark J. Graham,Robert Mckay,Amuthakannan Subramaniam,Stephanie Propp,Bridget Lollo,Susan M. Freier,C. Frank Bennett,Sanjay Bhanot,Brett P. Monia +16 more
TL;DR: IMR-122 inhibition in a diet-induced obesity mouse model resulted in decreased plasma cholesterol levels and a significant improvement in liver steatosis, accompanied by reductions in several lipogenic genes, suggesting that miR- 122 may be an attractive therapeutic target for metabolic disease.
Journal ArticleDOI
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Yoichi Nagata,Keng-Hsueh Lan,Xiaoyan Zhou,Ming Tan,Francisco J. Esteva,Aysegul A. Sahin,Kristine S. Klos,Ping Li,Brett P. Monia,Nina T. Nguyen,Gabriel N. Hortobagyi,Mien Chie Hung,Dihua Yu +12 more
TL;DR: In this paper, PTEN activation contributes to trastuzumab's antitumor activity and PI3K inhibitors rescued PTEN loss-induced trastusumab resistance.
Journal ArticleDOI
Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression
Brett P. Monia,Elena A. Lesnik,Carolyn Gonzalez,Walt F. Lima,Daniel Peter Claude Mcgee,Charles J. Guinosso,Andrew Mamoro Kawasaki,Phillip Dan Cook,Susan M. Freier +8 more
TL;DR: The use of a previously described 17-mer phosphorothioate for structure-function analysis of 2'-sugar modifications and the results demonstrate the importance of target affinity in the action of antisense oligonucleotides and of RNase H as a mechanism by which these compounds exert their effects.
Patent
Gapped 2' modified oligonucleotides
Phillip Dan Cook,Brett P. Monia +1 more
TL;DR: Oligonucleotides and macromolecules are useful for diagnostics and other research purposes, for modulating protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to antisense therapeutics as discussed by the authors.
Journal ArticleDOI
Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C- raf kinase
TL;DR: It is suggested that antisense inhibitors targeted against C–raf–1 kinase may be of considerable value as antineoplastic agents that display activity against a wide spectrum of tumor types at well–tolerated doses.